<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHSCOPOLAMINE BROMIDE - methscopolamine bromide tablet </strong><br>BAYSHORE PHARMACEUTICALS LLC<br></p></div>
<h1>
<span class="Bold">Methscopolamine Bromide Tablets, USP 2.5 mg and 5 mg</span><span class="Bold"><br></span><span class="Bold">
Bayshore Pharmaceuticals LLC</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Methscopolamine Bromide Tablets, USP 2.5 mg and 5 mg contain methscopolamine bromide USP, an anticholinergic, which occurs as white crystals, or as a white odorless crystalline powder. Methscopolamine bromide melts at about 225°C with decomposition. The drug is freely soluble in water, slightly soluble in alcohol, and insoluble in acetone and in chloroform.</p>
<p>The chemical name for methscopolamine bromide is 3-Oxa-9-azoniatricyclo [3.3.1.0<span class="Sup">2, 4</span>]nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9, 9-dimethyl-, bromide, [7(s)-(1α, 2β, 4β, 5α, 7β)]- and the molecular weight is 398.30.</p>
<p>The structural formula is represented below:</p>
<div class="Figure"><img alt="c265374e-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c74bfb0-c80a-4a86-acd1-1e3a1b20255d&amp;name=c265374e-figure-01.jpg"></div>
<p>Methscopolamine Bromide Tablets, USP 2.5 mg for oral administration contain 2.5 mg of methscopolamine bromide USP. Methscopolamine Bromide Tablets, USP 5 mg for oral administration contain 5 mg of methscopolamine bromide USP.</p>
<p>Inactive ingredients: microcrystalline cellulose NF, pregelatinized starch NF, colloidal silicon dioxide</p>
<p>NF, magnesium stearate NF.</p>
<p>Contains no lactose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>. Large doses may result in <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2><span class="Bold">PHARMACOKINETICS
</span></h2>
<p class="First">Methscopolamine bromide is a quaternary ammonium derivative of scopolamine. As a class, these agents are poorly and unreliably absorbed.<span class="Sup">1, 2 </span>Total absorption of quaternary ammonium derivatives of the alkaloids is 10 to 25%. Rate of absorption is not available. Quaternary ammonium salts have limited absorption from intact skin, and conjunctival penetration is poor.<span class="Sup">1</span> Little is known of the fate and excretion of most of these agents.<span class="Sup">1</span> Following oral administration, drug effects appear in about one hour and persist for 4 to 6 hours.<span class="Sup">2</span> Methscopolamine bromide has limited ability to cross the blood-brain barrier.<span class="Sup">3,4,5</span> The drug is excreted primarily in the urine and bile, or as unabsorbed drug in feces.<span class="Sup">2</span> There is no data on the presence of methscopolamine in breast milk; traces of atropine have been found after administration of atropine.<span class="Sup">1</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Adjunctive therapy for the treatment of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
<p>METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">PEPTIC ULCER</span>, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>; <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (e.g., <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> complicating <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Methscopolamine Bromide Tablets, USP 2.5 mg and 5 mg is contraindicated in patients who are</p>
<p>hypersensitive to methscopolamine bromide or related drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="be2469f3-bc29-4ff4-9ef2-4bcb5dba861f"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First">In the presence of high environmental temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>) can occur with drug use.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.</p>
<p>Methscopolamine bromide may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.</p>
<p>With overdosage, a curare-like action may occur, i.e., <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> leading to <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and possible <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">1. General precautions
</span></h2>
<p class="First">Use Methscopolamine Bromide Tablets, USP 2.5 mg and 5 mg with caution in the elderly and in all patients with: <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>; hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>; or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> –large doses may suppress intestinal motility to the point of producing a <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and for this reason precipitate or aggravate "toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>," a serious complication of the disease.</p>
<p>The drug also should be used with caution in patients having <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">2. Information for patient
</span></h2>
<p class="First">See statement under <span class="Bold"><a href="#be2469f3-bc29-4ff4-9ef2-4bcb5dba861f">WARNINGS</a></span><span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">3. Laboratory tests
</span></h2>
<p class="First">Progress of the <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> under treatment should be followed by upper gastrointestinal contrast radiology or endoscopy to insure healing. Stool tests for occult blood and blood hemoglobin or hematocrit values should be followed to rule out <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">4. Drug interactions
</span></h2>
<p class="First">Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2><span class="Bold">5. Carcinogenesis, mutagenesis, impairment of fertility
</span></h2>
<p class="First">No long-term studies in animals have been performed to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2><span class="Bold">6. Pregnancy
</span></h2>
<p class="First">Teratogenic effects</p>
<p>Pregnancy Category C. Animal reproduction studies have not been conducted with methscopolamine bromide. It is also not known whether methscopolamine bromide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methscopolamine bromide should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2><span class="Bold">7. Nursing mothers
</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methscopolamine bromide is administered to a nursing woman.</p>
<p>Anticholinergic drugs may suppress lactation.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.8"></a><p></p>
<h2><span class="Bold">8. Pediatric use
</span></h2>
<p class="First">Safety and efficacy in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The following adverse reactions have been observed, but there is not enough data to support an estimate of frequency.</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>.</p>
<p><span class="Bold">Allergic: </span>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or drug idiosyncrasies including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p><span class="Bold">CNS: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, dilation of the pupil, <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>, increased ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>.</p>
<p><span class="Bold">Renal: </span><span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary hesitancy</span> and retention.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">bloated feeling</span>.</p>
<p><span class="Bold">Dermatologic: </span>Decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and other dermal manifestations.</p>
<p><span class="Bold">Miscellaneous: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Xerostomia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, suppression of lactation.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</span></h1>
<p class="First">Not applicable.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">The symptoms of overdosage with Methscopolamine Bromide Tablets, USP 2.5 mg and 5 mg progress from intensification of the usual side effects to CNS disturbances (from <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> to <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> behavior), circulatory changes (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>Measures to be taken are (1) induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and (2) injection of physostigmine 0.5 to 2 mg intravenously, and repeated as necessary up to a total of 5 mg. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> may be treated symptomatically (alcohol sponging, ice packs). <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Excitement</span> of a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100 to 200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.</p>
<p>The oral LD<span class="Sub">50</span> in rats is 1,352 to 2,617 mg/kg.</p>
<p>No data is available on the dialyzability of methscopolamine bromide.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">The average dosage of Methscopolamine Bromide Tablets, USP is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects.</p>
<p>If the patient is experiencing symptoms such as severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or cramping which demand prompt relief, the drug may be started on a daily dosage of 20 mg, administered in doses of 5 mg one-half hour before meals and at bedtime. If very unpleasant side effects develop promptly, the daily dosage should be reduced. If neither symptomatic relief nor side effects appear, the daily dosage may be increased. Some patients have tolerated 30 mg daily with no unpleasant reactions.</p>
<p>Patients whose dosage has been reduced to eliminate or modify side effects often continue to show adequate response both subjectively in relief of symptoms and objectively as measured by antisecretory effects.</p>
<p>The ultimate aim of therapy is to arrive at a dosage which provides maximal clinical effectiveness with a minimum of unpleasant side effects. Many patients report no side effects on a dosage which gives complete relief of symptoms. On the other hand, some patients have reported severe side effects without appreciable symptomatic relief. Such patients must be considered unsuited for this therapy. Usually they have been or will prove to be similarly intolerant to other anticholinergic drugs. If methscopolamine bromide is to be used in a patient who gives a history of such intolerance, it should be started at a low dosage.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Methscopolamine Bromide Tablets, USP 2.5 mg are available as white, round tablets, debossed with "BY1" on one side and plain on the other side, in the following package size:</p>
<p>Bottles of 100 (NDC 76385-100-01)</p>
<p>Methscopolamine Bromide Tablets, USP 5 mg are available as white, oval tablets, debossed with "BY2" on one side and plain on the other side, in the following package size:</p>
<p>Bottles of 60 (NDC 76385-101-60)</p>
<p>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p><span class="Bold">KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1><span class="Bold">REFERENCES
</span></h1>
<p class="First">1. Gilman A, Gilman AB, Goodman LA, eds.</p>
<p><span class="Italics">The Pharmacological Basis of Therapeutics. </span>6th ed. New York: MacMillan Publishing Company.1980.</p>
<p>2. American Hospital Formulary Service. American Society of Hospital Pharmacists. Bethesda, Maryland.</p>
<p>3. Domino EF, Corasen G. Central and Peripheral Effects of Muscarinic Cholinergic Blocking Agents in</p>
<p>Man. <span class="Italics">Anesthesiology </span>1967;28:568-574.</p>
<p>4. Mogensen L, Orinius E. Arrhythmic Complications after Parasympathetic Treatment of <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">Bradyarrhythmias</span> in a Coronary Care Unit. <span class="Italics">Acta Med Scand </span>1971;190:495-498.</p>
<p>5. Neeld JB Jr., et al. Cardiac Rate and Rhythm Changes with Atropine and Methscopolamine. <span class="Italics">Clin Pharmacol Ther </span>1975;17(3):290-295.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088</span></p>
<p>Manufactured for:</p>
<p><span class="Bold">Bayshore Pharmaceuticals LLC</span></p>
<p>Short Hills, NJ 07078</p>
<p>1-800-593-5725</p>
<p>Issued: 01/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First">NDC 76385-100-01</p>
<p><span class="Bold">Methscopolamine</span></p>
<p><span class="Bold">Bromide Tablets,</span></p>
<p><span class="Bold">USP</span></p>
<p><span class="Bold">2.5 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">Bayshore</span></p>
<p><span class="Bold"><img alt="c265374e-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c74bfb0-c80a-4a86-acd1-1e3a1b20255d&amp;name=c265374e-figure-02.jpg"></span></p>
<p>NDC 76385-101-60</p>
<p><span class="Bold">Methscopolamine</span></p>
<p><span class="Bold">Bromide Tablets,</span></p>
<p><span class="Bold">USP</span></p>
<p><span class="Bold">5 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p><span class="Bold">Bayshore</span></p>
<p><span class="Bold"><img alt="c265374e-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5c74bfb0-c80a-4a86-acd1-1e3a1b20255d&amp;name=c265374e-figure-03.jpg"></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHSCOPOLAMINE BROMIDE 		
					</strong><br><span class="contentTableReg">methscopolamine bromide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76385-100</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHSCOPOLAMINE BROMIDE</strong> (METHSCOPOLAMINE) </td>
<td class="formItem">METHSCOPOLAMINE BROMIDE</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BY1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76385-100-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200602</td>
<td class="formItem">10/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHSCOPOLAMINE BROMIDE 		
					</strong><br><span class="contentTableReg">methscopolamine bromide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76385-101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHSCOPOLAMINE BROMIDE</strong> (METHSCOPOLAMINE) </td>
<td class="formItem">METHSCOPOLAMINE BROMIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BY2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76385-101-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200602</td>
<td class="formItem">10/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>BAYSHORE PHARMACEUTICALS LLC
							(968737416)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>BAYSHORE PHARMACEUTICALS LLC (968737416)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">SUNRISE PHARMACEUTICAL, INC.</td>
<td class="formItem"></td>
<td class="formItem">168522378</td>
<td class="formItem">MANUFACTURE(76385-100, 76385-101)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c265374e-9962-4004-a74b-6605330055c7</div>
<div>Set id: 5c74bfb0-c80a-4a86-acd1-1e3a1b20255d</div>
<div>Version: 2</div>
<div>Effective Time: 20131028</div>
</div>
</div> <div class="DistributorName">BAYSHORE PHARMACEUTICALS LLC</div></p>
</body></html>
